This article introduces the largest foundations in the world, fostering changes and improvements across various sectors to ...

Variant Bio, a small biotech company based in Seattle, is using genetic information from Indigenous people to develop drugs ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Comparing Tyrzepatide and Semaglutide in the slimming drug market, with potential growth driven by increasing obesity rates worldwide. Explore more here.

Meta, Amazon Web Services, Novo Nordisk, xAI took top honors in Business Facilities’ 2024 Deal Of The Year Awards, ...

Novo Nordisk's prospects look attractive despite a recent clinical setback. AstraZeneca would be performing well if not for ...

The U.S. FDA has approved Alhemo, given as once-daily injections, to help prevent bleeds in patients with hemophilia A or B ...

The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...

Right now, Novo stock is trading at a forward price-to-earnings (P/E) multiple of 22.5 -- its lowest level in well over a year. I think now is a terrific opportunity to scoop up shares of Novo on the ...

Novo Nordisk (NVO) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the ...

Nordic firms have outperformed those from the rest of Europe over the past decade. In all four countries, listed ...

INR:0330. ace 2 three plus 4 Novo Nordisk's Fiasp is approved in Canada for use in pediatric patients aged ≥ 2 years! After much anticipation, this new breas ...